BioXcel Therapeutics, Inc.
Other OTCTotal Valuation
BioXcel Therapeutics, Inc. carries a market capitalization of 1.63M, placing it among publicly traded companies globally. Its enterprise value stands at 91.61M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.63M |
| Enterprise Value | 91.61M |
Share Statistics
BioXcel Therapeutics, Inc. currently has 31.31M shares outstanding.
| Shares Outstanding | 31.31M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 123.46 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
BioXcel Therapeutics, Inc. maintains a current ratio of 0.21, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -90.47, indicating conservative leverage, while an interest coverage ratio of -2.58 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.21 |
| Quick Ratio | 0.09 |
| Debt / Equity | -90.47 |
| Debt / EBITDA | -2.35 |
| Interest Coverage | -2.58 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -259.62 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.70 |
Stock Price Statistics
BioXcel Therapeutics, Inc.'s stock has declined approximately -94.39595% over the past 52 weeks. The 50-day moving average sits at 0.48, while the 200-day moving average is 1.16.
| Beta (5Y) | N/A |
| 52-Week Price Change | -94.39595% |
| 50-Day Moving Average | 0.48 |
| 200-Day Moving Average | 1.16 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, BioXcel Therapeutics, Inc. generated 742,000.00 in revenue and converted that into -70.86M in net income, yielding earnings per share of -3.12. EBITDA reached -44.51M, while operating income came in at -44.73M.
| Revenue | 742,000.00 |
| Gross Profit | 394,000.00 |
| Operating Income | -44.73M |
| Pretax Income | -70.86M |
| Net Income | -70.86M |
| EBITDA | -44.51M |
| EBIT | -44.73M |
| Earnings Per Share (EPS) | -3.12 |
Balance Sheet
BioXcel Therapeutics, Inc. holds 12.84M in cash and equivalents against 104.45M in total debt, resulting in a net debt position of 91.61M. Total book value stands at -115.46M, with working capital of -108.45M providing operational flexibility.
| Cash & Cash Equivalents | 12.84M |
| Total Debt | 104.45M |
| Net Debt | 91.61M |
| Equity (Book Value) | -115.46M |
| Book Value Per Share | -3.69 |
| Working Capital | -108.45M |
Cash Flow
BioXcel Therapeutics, Inc. produced -50.90M in operating cash flow over the past twelve months.
| Operating Cash Flow | -50.90M |
| Capital Expenditures | N/A |
| Free Cash Flow | -50.90M |
| FCF Per Share | -2.24 |
Margins
BioXcel Therapeutics, Inc. operates with a gross margin of 53.10, reflecting its pricing power and cost economics. The operating margin of -6,028.57 and net profit margin of -9,549.87 provide insight into operational efficiency.
| Gross Margin | 53.10 |
| Operating Margin | -6,028.57 |
| Pretax Margin | -9,549.87 |
| Profit Margin | -9,549.87 |
| EBITDA Margin | -5,998.25 |
Scores
BioXcel Therapeutics, Inc. posts an Altman Z-Score of -45.96, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -45.96 |